TD Cowen raises Avita Medical stock price target on PermeaDerm data
TD Cowen has increased its price target for Avita Medical (NASDAQ:RCEL) to $14.00 from $12.00, maintaining a Buy rating, citing enhanced confidence in PermeaDerm's commercial potential after positive clinical trial data and surgeon endorsements. The stock has surged 185% year-to-date, trading near its 52-week high, while recent financial reports also showed Avita Medical exceeding revenue estimates in Q2.
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
A new study by Avita Medical demonstrated that its PermeaDerm product reduced treatment costs by 70% compared to cadaveric allograft for temporary wound coverage, costing $148.70 versus $497.10 per 1% of total body surface area treated. The biosynthetic wound matrix also significantly cut preparation time while showing comparable graft take, application time, and eight-week wound healing outcomes. Surgeons noted PermeaDerm's standardized design, easier logistics, and potential use in larger burns, highlighting its transparency and consistent supply.
BTIG raises Avita Medical stock price target on positive trial data
BTIG has increased its price target for Avita Medical (NASDAQ:RCEL) to $11.00 from $7.00, maintaining a Buy rating, following positive results from the company's PermeaDerm-I study. This study demonstrated a significant economic advantage over allograft and comparable clinical outcomes, with PermeaDerm and Cohealyx expected to diversify Avita Medical’s revenue and growth. The stock has seen a substantial surge year-to-date, and analysts have revised earnings estimates upward, reflecting strong financial performance and strategic moves by the company.
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts
Avita Medical Inc. (NASDAQ:RCEL) has received a "Moderate Buy" consensus rating from analysts, with five out of seven recommending a buy. The average 12-month price target is $8.25. The company recently reported better-than-expected quarterly earnings and revenue, and insiders have purchased 35,200 shares in the last three months.
RCEL Looks 21.8% Undervalued on GF Value™
Avita Medical Inc (NASDAQ: RCEL) has released positive results for its PermeaDerm-I clinical trial, showing its wound matrix is as effective as traditional allografts but 70% cheaper. Despite this, the company remains unprofitable and cash-flow negative, reflected in its high Price-to-Sales ratio. GuruFocus's GF Value™ suggests RCEL is 21.8% undervalued, while insider buying signals confidence in its future.
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical has announced positive results from its PermeaDerm-I clinical study, showing that its biosynthetic wound matrix, PermeaDerm, provides comparable clinical outcomes to cadaveric allograft while offering a 70% economic advantage due to lower product cost and reduced preparation time. The study demonstrated significant cost savings per percent of total body surface area treated and comparable wound healing and safety profiles. This positions PermeaDerm as an efficient and economically favorable alternative for temporary wound coverage.
AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com
AVITA Medical announced that its PermeaDerm-I clinical study demonstrated a 70% reduction in treatment costs compared to cadaveric allograft while maintaining similar clinical outcomes. The study involved 40 patients across 11 U.S. burn centers, showing significant cost savings per percent total body surface area treated. PermeaDerm also reduced preparation time by 95.7% and showed comparable wound healing rates, with no adverse events attributed to the product.
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical announced positive results from its PermeaDerm-I study, showing its biosynthetic wound matrix, PermeaDerm, offers a 70% economic advantage over cadaveric allograft due to significantly lower product cost and 95.7% reduced preparation time. The study demonstrated comparable clinical outcomes to allograft, with high rates of graft take and wound healing, and no PermeaDerm-attributed adverse events. These findings establish PermeaDerm as an efficient and cost-effective alternative for temporary wound coverage.
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical reported strong second-quarter 2026 revenue of $21.7 million, an 18% increase year-over-year, leading the company to raise its full-year revenue guidance to $86 million to $89 million. The company expects continued sequential revenue growth and reiterated its goal to achieve cash-flow breakeven in Q4 2026, driven by product portfolio expansion, improved reimbursement clarity, and international market progress.
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
Avita Medical (RCEL) expects to achieve cash flow breakeven in Q4 2025, driven by continued sequential revenue growth and controlled operating expenses. CEO Cary Vance highlighted the company's focus on hospital-based acute wound care with a three-product portfolio, targeting a $1.3 billion U.S. addressable market. The company also addressed past reimbursement challenges and plans for future growth beyond breakeven.
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical (NASDAQ: RCEL) has increased its 2026 revenue guidance to $86 million–$89 million, up from $80 million–$85 million, after a strong second quarter where sales grew 18% year-over-year to $21.7 million. The wound-care company is also on track to achieve cash-flow breakeven in the fourth quarter of 2026, driven by improved financial performance, a narrowed net loss, and reduced cash usage. Growth is expected from increased adoption of its products, potential reimbursement changes from CMS, and international expansion.
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical (NASDAQ: RCEL) has raised its 2026 revenue guidance to $86 million–$89 million after its second-quarter revenue grew 18% year over year to $21.7 million. The company aims for cash-flow breakeven in Q4 2026 and reported a narrower net loss of $7.7 million and reduced cash use. Growth is expected from its product portfolio, potential CMS reimbursement changes, and international expansion.
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
Avita Medical (NASDAQ: RCEL) aims to achieve cash flow breakeven in Q4 2025, driven by strong revenue growth and disciplined operating expenses. The company has raised its 2025 revenue guidance to $86 million–$89 million and expects continued expansion for its wound care product portfolio, which currently has about 15% penetration in its core U.S. market. Easing reimbursement uncertainty is also supporting their growth trajectory.
Avita Medical amends agreement with Stedical Scientific to expand distribution rights
Avita Medical has amended its distribution and manufacturing agreements with Stedical Scientific, securing a right of first offer and refusal to expand its exclusive distribution territory for PermeaDerm products to include the EU, UK, and Australia. The amendment also increases Avita Medical's revenue share from PermeaDerm sales and waives previous minimum revenue sharing payments. This strategic move follows Avita Medical's strong second-quarter earnings report, which exceeded revenue expectations and led to an analyst upgrade.
Form 8K Avita Medical Ltd For: 11 August By Investing.com
This article announces the filing of a Form 8K by Avita Medical Ltd, dated August 11. It's a brief report from Investing.com, typical of regulatory filing announcements. The article provides financial data for various indices, commodities, bonds, and shares, as well as a list of popular news and trending stocks.
AVITA Medical Inc (ASX:AVH) Shares Reach 52-Week High at AUD 2.30
AVITA Medical Inc (ASX:AVH) shares reached a new 52-week high of AUD 2.30 on August 12, 2026, closing at AUD 2.28 after a 7.04% increase. The company's market capitalization was approximately AUD 381.9 million, with the stock trading near the top of its annual range of AUD 1.00 to AUD 2.30. This performance highlights significant market activity for AVITA Medical, placing it among healthcare stocks reaching new highs.
Avita Medical amends agreement with Stedical Scientific to expand distribution rights
Avita Medical (NASDAQ:RCEL) has amended its distribution and manufacturing agreements with Stedical Scientific, securing rights to expand PermeaDerm product distribution into Europe, the UK, and Australia. The agreement increases Avita Medical's revenue share from PermeaDerm sales and waives previous minimum payment requirements. This follows Avita Medical's strong Q2 earnings, which led BTIG to upgrade its stock rating to Buy.
Avita Medical Target Price Raised 52% to A$1.90/Share by Canaccord Genuity>AVH.AU
Canaccord Genuity has increased its target price for Avita Medical (AVH.AU) by 52%, setting a new target of A$1.90 per share. This upgrade suggests a strong positive outlook from the analyst firm regarding Avita Medical's future performance.
Investors Can Question AVITA Medical Executives on Aug. 12
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, 9:00 a.m. AEST). President and CEO Cary Vance and CFO David O’Toole will present financial and business highlights from the recent Q2 2026 earnings webcast. Investors can register via Zoom to participate in a Q&A session, and a replay will be available on the company's investor relations website.
AVITA Medical to Host Investor Webinar Briefing | Associated Press | syndication news
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing and presentation on August 12, 2026, at 4:00 p.m. Pacific Time. The webinar will feature President and CEO Cary Vance and CFO David O’Toole, covering second-quarter 2026 earnings and including a Q&A session. A replay will be available on the AVITA Medical website.
AVITA Medical, Inc. (NASDAQ:RCEL) Is Expected To Breakeven In The Near Future
This article analyzes AVITA Medical, Inc.'s path to profitability, focusing on analyst forecasts for its breakeven point and revenue growth. It highlights the company's expected strong revenue growth and significant earnings improvement in the coming years. The analysis also briefly touches on the importance of management's track record and financial health for future success.
Avita Medical Upgraded to Speculative Buy From Speculative Hold by Bell Potter
Bell Potter has upgraded Avita Medical (ASX:AVH) from a "Speculative Hold" to a "Speculative Buy" rating. This upgrade indicates a more positive outlook on the company's stock by the analyst firm.
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing on August 12, 2026, featuring CEO Cary Vance and CFO David O'Toole. The briefing will cover financial and business results from the company's second-quarter 2026 earnings and will include a Q&A session. Shareholders and prospective investors are invited to register via Zoom, with a replay available on the AVITA Medical website.
Avita Medical (NASDAQ:RCEL) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
Avita Medical (NASDAQ:RCEL) announced its quarterly earnings, beating analyst estimates with an adjusted loss of $0.25 per share on revenue of $21.7 million. The company's revenue increased 18% year-over-year, driven by strong RECELL sales, and management raised its 2026 revenue guidance. Avita Medical expects to achieve cash-flow breakeven in the fourth quarter of 2026.
Avita Medical Q2 Earnings Call Highlights
Avita Medical reported strong Q2 2026 results with revenue of $21.7 million, an 18% year-over-year increase, driven by growth in its RECELL product and newer offerings like Cohealyx and PermeaDerm. The company raised its full-year revenue outlook to $86 million to $89 million and anticipates achieving cash-flow breakeven in Q4 2026. Improvements in physician reimbursement for RECELL and the upcoming transition to a new CPT code family are expected to further streamline growth and financial stability.
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
AVITA Medical, a therapeutic acute wound care company, announced its participation in the Canaccord Genuity 46th Annual Growth Conference. President and CEO Cary Vance will speak on August 12, 2026, and a webcast will be available for investors. The company specializes in solutions like RECELL, Cohealyx, and PermeaDerm for wound healing.
AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ...
AVITA Medical Inc (AVHHL) reported strong Q2 2026 results with revenue surging 18% year-over-year to $21.7 million, exceeding $20 million for the first time. The company raised its full-year 2026 revenue guidance and anticipates achieving cash flow breakeven by Q4 2026. While operating and net losses improved, cash reserves remain relatively low, and the company faces challenges with new product adoption and potential transitional impacts from CPT code changes.
Avita Medical Q2 Earnings Call Highlights
Avita Medical (RCEL) reported strong second-quarter 2026 results, with revenue up 18% year-over-year to $21.7 million, driven by its RECELL product and newer offerings like Cohealyx and PermeaDerm. The company raised its full-year revenue outlook to $86 million to $89 million and anticipates reaching cash-flow breakeven in Q4 2026. Improvements in physician reimbursement for RECELL and the upcoming transition to a new CPT code family are expected to further streamline operations and growth.
Press Release: AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
AVITA Medical announced its second-quarter results, showcasing significant growth with record revenue and a raised full-year 2026 revenue guidance. The company reported strong performance from its RECELL GO device and anticipates achieving cash flow breakeven in the fourth quarter of 2026. This positive outlook is supported by increased sales, expanding market penetration, and strategic product development.
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
AVITA Medical, Inc. announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11–13, 2026. The company's President and CEO, Cary Vance, is scheduled to speak on August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay of his presentation will be available on Avita Medical's investor relations website, and investors attending the conference can request one-on-one meetings with the company.
CEO Cary Vance to Speak at AVITA Medical Conference Aug. 12
AVITA Medical (NASDAQ: RCEL, ASX: AVH) announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11–13, 2026. President and CEO Cary Vance is scheduled to speak on August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available on AVITA Medical’s investor relations website, and investors attending can request one-on-one meetings with the company.
Avita Medical upgrades FY26 revenue guidance
Avita Medical announced a reduced statutory net loss of USD7.7 million for the June quarter and updated its full-year 2026 net revenue guidance to between USD86 million and USD89 million, an increase from its previous forecast. The company also anticipates achieving cashflow breakeven in the fourth quarter. No dividend was declared.
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
AVITA Medical reported strong second-quarter 2026 financial results, with net revenue growing 18% year-over-year to a record $21.7 million, driven by the success of RECELL, Cohealyx, and PermeaDerm. The company raised its full-year 2026 net revenue guidance to $86 million to $89 million and anticipates achieving cash flow breakeven in the fourth quarter of 2026. This positive outlook is supported by continued commercial execution and disciplined operating expenses.
Earnings call transcript: AVITA Medical tops Q2 2026 estimates, shares jump
AVITA Medical reported better-than-expected Q2 2026 results, with narrower losses and higher revenue, leading to an 11.42% after-hours stock jump. The company raised its full-year 2026 revenue guidance to $86 million-$89 million and expects to achieve cash flow breakeven by Q4 2026. Management highlighted strong growth in its wound care portfolio, improved operating efficiency, and positive momentum from product adoption and reimbursement clarity.
AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ...
AVITA Medical (AVHHL) reported strong Q2 2026 results with revenue up 18% year-over-year to $21.7 million, exceeding $20 million for the first time. The company raised its full-year 2026 revenue guidance and anticipates achieving cash flow breakeven by Q4 2026. While operating and net losses improved, the company is focused on expanding adoption of its RECELL GO mini, Cohealyx, and PermeaDerm products, navigating CPT code transitions, and managing gross margins.
AVITA Medical Reports Revenue Growth and Targets Cash Flow Breakeven in 2026
AVITA Medical (ASX:AVH) reported significant revenue growth in Q2 2026, driven by its RECELL, Cohealyx, and PermeaDerm products. The company raised its full-year 2026 revenue guidance to $86 million-$89 million and anticipates achieving cash flow breakeven in the fourth quarter of 2026. This positive outlook is supported by commercial expansion, improved operating efficiency, and potential Medicare payment updates for RECELL.
Earnings call transcript: AVITA Medical tops Q2 2026 estimates, shares jump
AVITA Medical (RCEL) exceeded Q2 2026 earnings estimates, reporting a narrower loss of $0.25 per share and revenue of $21.7 million, surpassing forecasts. The company raised its full-year 2026 revenue guidance to $86 million-$89 million and expects to achieve cash flow breakeven and generate cash by Q4 2026, driven by strong growth in its wound-care portfolio and improved operating discipline. Shares jumped over 11% in after-hours trading following the positive results and outlook.
AVITA Medical Inc reports results for the quarter ended June 30 - Earnings Summary
AVITA Medical Inc has released its earnings summary for the quarter that ended on June 30. The full article, available via Reuters on TradingView, provides detailed financial results for the period.
AVITA Medical expects cash flow breakeven in fourth quarter 2026
AVITA Medical (NASDAQ: RCEL) reported strong Q2 2026 results with record revenue of $21.7 million, an 18% year-over-year increase, driven by its RECELL, Cohealyx, and PermeaDerm products. The company raised its full-year 2026 revenue guidance to $86–$89 million and anticipates achieving cash flow breakeven in the fourth quarter of 2026. This positive outlook is supported by disciplined operating expenses, improved cash use, and proposed favorable Medicare payment updates for RECELL procedures.
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
AVITA Medical reported strong second-quarter 2026 results, with net revenue growing 18% year-over-year to $21.7 million, driven by the performance of RECELL, Cohealyx, and PermeaDerm. The company raised its full-year 2026 revenue guidance to $86 million to $89 million and anticipates achieving cash flow breakeven in the fourth quarter of 2026. This positive outlook is supported by disciplined operating expenses, improved cash management, and proposed favorable Medicare payment updates for RECELL in 2027.
AVITA Medical Q2 revenue rises 18% to $21.7M; raises 2026 guidance, expects Q4 cash-flow breakeven
AVITA Medical reported strong Q2 2026 financial results with revenue increasing 18% year-over-year to $21.7 million, driven by the success of RECELL, Cohealyx, and PermeaDerm. The company narrowed its net loss and raised its full-year 2026 revenue guidance to $86-$89 million, projecting cash-flow breakeven by Q4 2026. This positive outlook is further supported by potential favorable Medicare payment updates in 2027.
Wall Street Zen Upgrades Avita Medical (NASDAQ:RCEL) to "Hold"
Wall Street Zen has upgraded Avita Medical (NASDAQ:RCEL) from a "sell" to a "hold" rating, aligning with the overall consensus "hold" rating from analysts. The company's shares opened at $4.40, and it recently reported quarterly revenue of $19.25 million, exceeding analyst estimates, while EPS matched expectations at -$0.35. Insider purchases totaling $155,080 have occurred recently, and institutional investors now own 27.66% of the company.
AVITA Medical Inc (RCEL) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of AVITA Medical Inc (RCEL), which currently holds a financial score of 7.74, ranking 85 out of 384 in its industry. Despite a weak financial status, the company shows high operating efficiency, with its latest quarterly revenue increasing by 3.98% year-over-year and net profit rising by 23.44%. The report delves into specific financial dimensions such as quality of earnings, operational efficiency, growth potential, and shareholder returns.
AVITA Medical Inc (RCEL) Institutional Confidence
AVITA Medical Inc (RCEL) has an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 22.36% quarter-over-quarter to 21.20%. Bill Nygren | OAKMX is the largest institutional shareholder, despite significantly decreasing its holdings.
Avita Medical (RCEL) Projected to Announce Earnings on Thursday
Avita Medical (NASDAQ:RCEL) is anticipated to report its Q2 2026 earnings after market close on Thursday, August 6th, with analysts forecasting a loss of $0.2928 per share and revenue of $20.25 million. The company recently met previous EPS expectations and exceeded revenue estimates. Despite mixed analyst sentiment leading to a "Hold" rating, a director recently increased their stake in the company.
RCEL|AVITA Medical Inc|Price:4.760|Chg%:+0.150
This article provides a comprehensive stock analysis of AVITA Medical Inc (RCEL) from TradingKey, highlighting its stable fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. Analysts rate it as a Buy with a target upside of over 50%, despite its stock currently trading sideways. The company, known for its RECELL System for wound healing, shows strong revenue and profit growth.
AVITA Medical Inc (RCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for AVITA Medical Inc (RCEL), indicating a current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts project an average price target of 5.50 USD for RCEL, with a majority recommending a "Buy" trend. The company's expected revenue for the next quarter is 20.17M USD, and the expected EPS for the next quarter is -0.29 USD.
AVITA Medical Inc (RCEL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of AVITA Medical Inc (RCEL), identifying its major institutional holders and their proportional ownership. It also provides a breakdown of shareholder types and a historical view of institutional shareholding trends and activities, including changes in holdings by key institutions.
AVITA Medical Inc (RCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for AVITA Medical Inc (RCEL), focusing on its regional revenue contributions. The data shows that the United States accounts for the vast majority of revenue at 96.06% ($68.79M), followed by Japan, the United Kingdom, Australia, and the European Union. Information regarding business segments and profit contribution has not yet been disclosed by the company.
AVITA Medical Inc (RCEL) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for AVITA Medical Inc (RCEL), covering operating, investing, and financing activities. It presents financial data including net income, operating gains/losses, changes in working capital, capital expenditures, and free cash flow. The article also includes an FAQ section defining key cash flow metrics and detailing RCEL's performance in these areas, such as its operating cash flow of -31.20M in fiscal 2025 and a 36.26% year-over-year increase in operating cash flow.
